Having observed the potentiating effects of USP2 inhibition toward 17-AAG-induced ErbB2 downregulation, we reasoned that the USP2 inhibitor ML364 might sensitize ErbB2-positive breast cancer cells to HSP90 inhibition and accordingly investigated the effectiveness of the combined treatment. This evidence concerns the gene USP2 and breast carcinoma.